+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications



Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications



Proceedings of the National Academy of Sciences of the United States of America 91(16): 7742-7746



Vascular complications are an important cause of morbidity and mortality in patients with diabetes. The extent of vascular complications has been linked statistically to enhanced adherence of diabetic erythrocytes to endothelial cells (ECs) and to the accumulation of a class of glycated proteins termed advanced glycation end products (AGEs). We hypothesized that formation of AGEs on the surface of diabetic erythrocytes could mediate their interaction with ECs leading to binding and induction of vascular dysfunction. Enhanced binding of diabetic erythrocytes to ECs was blocked by preincubation of erythrocytes with anti-AGE IgG or preincubation of ECs with antibodies to the receptor for AGE (RAGE). Immunoblotting of cultured human ECs and immunostaining of normal/diabetic human tissue confirmed the presence of RAGE in the vessel wall. Binding of diabetic erythrocytes to endothelium generated an oxidant stress, as measured by production of thiobarbituric acid-reactive substances (TBARS) and activation of the transcription factor NF-kappa B, both of which were blocked by probucol or anti-RAGE IgG. Erythrocytes from diabetic rats infused into normal rats had an accelerated, early phase of clearance that was prevented, in part, by antibody to RAGE. Liver tissue from rats infused with diabetic erythrocytes showed elevated levels of TBARS, which was prevented by pretreatment with anti-RAGE IgG or probucol. Thus, erythrocyte surface AGEs can function as ligands that interact with RAGE on endothelium. The extensive contact of diabetic erythrocytes bearing surface-associated AGEs with vessel wall RAGE could be important in the development of vascular complications.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 045181832

Download citation: RISBibTeXText

PMID: 8052654

DOI: 10.2307/2365361


Related references

Diabetic erythrocytes bearing cell surface advanced glycation endproducts interact with the receptor for advanced glycation endproducts to induce oxidant stress in endothelium and increase vascular permeability. Circulation 90(4 PART 2): I576, 1994

Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. American Journal of Pathology 150(2): 523-531, 1997

Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects. Clinical and Experimental Medicine 7(4): 188-190, 2008

Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications. Cardiovascular Diabetology 14: 2, 2016

Advanced Glycation End Products (Ages) and Diabetic Vascular Complications. Current Diabetes Reviews 1(1): 93-106, 2005

Advanced glycation end products (AGEs) and diabetic vascular complications. Current Diabetes Reviews 1(1): 93-106, 2008

Advanced glycation end-products induce oxidative stress through the Sirt1/Nrf2 axis by interacting with the receptor of AGEs under diabetic conditions. Journal of Cellular Biochemistry 2018, 2018

Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opinion on Investigational Drugs 17(7): 983-996, 2008

The role of advanced glycation end-products (AGEs) in the development of vascular diabetic complications. Arquivos Brasileiros de Endocrinologia E Metabologia 52(6): 940-950, 2008

Advanced glycation end products (AGEs), oxidative stress and diabetic retinopathy. Current Pharmaceutical Biotechnology 12(3): 362-368, 2011

Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy. Current Pharmaceutical Design 14(10): 962-968, 2008

Role of Advanced Glycation End Products (Ages) and Oxidative Stress in Diabetic Retinopathy. Current Pharmaceutical Design 14(10): 962-968, 2008

Molecular mechanism of diabetic retinopathy: role of advanced glycation end products(AGEs) and their receptor (RAGE) in the pathogenesis of diabetic retinopathy. Nippon Ganka Gakkai Zasshi 109(6): 338-345, 2005

Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy. Current Drug Discovery Technologies 3(1): 83-88, 2006

Advanced Glycation End Products (Ages) and their Receptor (Rage) System in Diabetic Retinopathy. Current Drug Discovery Technologies 3(1): 83-88, 2006